Anuh Pharma (506260) Q4 99/00 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 99/00 earnings summary
23 Oct, 2026Executive summary
FY ended 31 Mar 2000: sales and operating income rose 50% YoY to Rs 195.59m; PBT reached Rs 31.64m and PAT Rs 24.34m.
Exports represented nearly 50% of sales; recognition as an Export House was received from the Government of India.
Financial highlights
Total income was Rs 204.99m vs Rs 137.33m YoY; total expenditure was Rs 173.35m vs Rs 116.24m.
PBT increased to Rs 31.64m from Rs 21.09m; tax provision was Rs 7.30m vs Rs 5.00m; PAT was Rs 24.34m vs Rs 16.09m.
Other income rose to Rs 9.41m from Rs 6.52m, including interest income of Rs 7.73m and dividend income of Rs 1.39m.
Outlook and guidance
Further export sales promotion planned to drive a sizeable increase in export turnover; satisfactory turnover and profits expected in the current year, barring unforeseen circumstances.
Latest events from Anuh Pharma
- Sales and exports grew as the new Tarapur API facility came on stream.506260
Q4 06/07 - Profit rose despite weaker sales; a 1:1 bonus issue and 50% dividend were proposed.506260Q4 97/98
- Profit rose despite falling sales, with export growth and deposit-compliance concerns.506260Q4 98/99
- PAT rose to ₹39.80m as exports grew and Tarapur capacity expansion began.506260Q4 01/02
- Sales grew 11.6%, exports surged, and PAT softened; dividend rose to ₹12.50/share.506260Q4 02/03
- Sales rose 50.1%, exports 46.5%, and PAT reached Rs 60.3m in FY04.506260Q4 03/04
- Profit fell amid export weakness; a new factory targets ~70% more capacity.506260Q4 04/05
- Sales rose 49.14%, PAT grew 41.57%, and the new factory came on stream.506260Q4 05/06
- FY08 sales rose 35%, PAT grew 13.29%, and 150 MT of capacity was planned.506260Q4 07/08